• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld Perspectives

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

Utopia, dystopia: Separating truth from fiction in bioethics discussions

June 2, 2015
By Jennifer Boggs
Let’s face it: Imagining the means of humanity’s ultimate destruction makes for great entertainment. There are no shortages of novels, movies and television shows featuring threats of global annihilation – zombie viruses, meteors hurtling through space, nuclear warfare – or opening up post-apocalyptic landscapes laid waste following a collision of unchecked scientific and technologic advances with the those worst of human traits – greed, irresponsibility, megalomania. And as an unabashedly enthusiastic science fiction fan, I love that stuff. So, naturally, when anyone starts talking game-changing technologies such as DNA cloning or CRISPR, my brain almost immediately goes rifling through its...
Read More

A world of intrigue, from Missoula to Mars: BioWorld’s 9th Annual Summer Reading List

May 26, 2015
By Marie Powers
Summer is not officially here, according to the calendar, but the first long weekend of the season brings thoughts of beaches, mountains, travel, relaxation, lazy days and active ones. No matter what floats your boat over summer vacation, a good book should never be far away. With that in mind, assembled once again for your reading pleasure is BioWorld’s Summer Reading List – our 9th annual edition. Be forewarned: Our respondents dug deep this year, tackling a variety of thoughtful and complex issues. You won’t find any fluff on these pages, but you’ll certainly find opportunities to be dazzled and...
Read More

You’ve come a long way, baby, but still a long way to go

May 4, 2015
By Mari Serebrov
Patients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds researchers, drugmakers and regulators that, “Hey, this is all about us!” While major drugmakers have been hiring senior-level staff to connect and interact with patients and to incorporate the patient perspective into their R&D for a while now, the regulatory field is making slim – albeit positive – advances in that direction. In the past, patients often testified during the...
Read More

As researchers unlock the brain’s mysteries, let’s not overlook the real questions

April 27, 2015
By Marie Powers
Covering the American Academy of Neurology's (AAN) 67th annual meeting in Washington – a gathering of nearly 13,000 clinicians, researchers, students, industry reps and even a few patients – was an exercise in exhaustion and a labor of love. I have a vested interest in this space, having lost my mother to glioblastoma before I reached my teens and my mother-in-law, just months ago, to Alzheimer’s disease. An even more compelling interest is the well-being of my husband, who was diagnosed with epilepsy at age 15, a year after a head injury during a soccer game. At age 40, he...
Read More

Talk to your doctor: How even annoying DTC ads can contribute to patient communication

April 15, 2015
By Jennifer Boggs
A few years ago I went to the nearby immediate care with a minor but irritating cough that wouldn’t go away. Three visits later – after two utterly ineffectual rounds of antibiotics and a prescription for a cough medicine that didn’t alleviate my cough though it helpfully revealed that I should never take codeine – I finally started digging around online. My search led me to a condition that explained my cough as well as a couple of other minor symptoms I hadn’t even thought to mention during my earlier visits because they didn’t seem related. I returned to the...
Read More

Sharing deeply of ourselves: Still messy

March 27, 2015
By Michael Fitzhugh
In the capital of digital sharing and over-sharing, Silicon Valley, contributing one’s whole genome to science in the name of fun and self-knowledge has never felt that controversial. Engineers share software code liberally every day on sites like GitHub and Bitbucket. Plenty of those same coders and their investors gleefully joined 23andMe spit parties back in the heady days before the Federal Trade Commission jumped in with a call to sanity. Silicon Valley is still over-sharing. Someone is literally live-streaming their walk from a train station to a bar on Twitter’s new Periscope app as I write. Superficially, it seems...
Read More

Patient engagement as important as the data

Feb. 13, 2015
By Mari Serebrov
The thought of having unfettered access to all the medical and genomic data of a million Americans had researchers gathered at the National Institutes of Health’s first workshop on precision medicine licking their lips. Almost giddy with excitement, they contemplated the endless opportunities for “really big audacious research” that could lead to a man-on-the moon moment in unlocking the mysteries of life and disease. As a patient recently diagnosed with two forms of cancer – a type of breast cancer known only for what it isn’t and an indolent lymphoma for which there is no cure – I shared their...
Read More

Listening to the voice that matters

Feb. 4, 2015
By Mari Serebrov
Since being diagnosed with cancer a few months ago, I have been in an unwanted crash course on the patient perspective of everything I’ve been writing about biopharma for the past several years. It’s an eye-opener. Genetic testing, lack of research, unmet medical need, off-label use, drug shortages, adverse events, informed consent, clinical trial data that don’t represent real-world practice, drug-drug interactions, co-morbidities, labeling precautions, reimbursement, data-sharing vs. privacy issues. ... Up until now, these were all topics I wrote about or discussed with my colleagues during our news meetings. Now, they’re personal. They impact my daily life and could...
Read More

States move forward as SEC lags on crowdfunding rules

Jan. 29, 2015
By Michael Fitzhugh
With a new year, old impatience is growing among small companies and investors eager to see the potential of federally sanctioned crowdfunding take off. In January, biotech hotbed Massachusetts, as well as Oregon and Maine, joined a growing list of states taking matters into their own hands. Irritated by the SEC's sauntering approach to finalizing proposed rules it drafted to implement crowdfunding provisions in the 2012 Jumpstart Our Business Startups (JOBS) Act, they joined a growing roster of states that have adopted their own rules for governing the offerings. (See BioWorld Insight, Aug. 11, 2014.) Massachusetts' new rules, like all...
Read More

Crowdfunding's slow march

Jan. 29, 2015
By Michael Fitzhugh
...
Read More
Previous 1 2 3 4 5 6 7 8 9 … 22 23 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 21, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 21, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for May 20, 2025
  • Scorpion Therapeutics patents p53 Y220 mutant activators

    BioWorld Science
    Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the...
  • Drug capsule and dollar sign

    Little bite from voluntary most-favored nation Rx pricing order

    BioWorld
    After a week of hype, the most-favored nation (MFN) drug pricing executive order (EO) U.S. President Donald Trump signed May 12 has a lot of bark but little bite,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe